耐多药结核病化疗研究的新进展

被引：17

作者：

唐神结

肖和平

张青

机构：

[1] 同济大学附属上海市肺科医院上海市结核(肺)重点实验室

来源：

中华结核和呼吸杂志 | 2009年 / 08期

关键词：

D O I：

暂无

中图分类号：

R686 [筋腱、韧带、滑囊疾病及损伤];

学科分类号：

摘要：

<正> 耐多药结核病(multidrug-resistant tuberculosis,MDR-TB)的流行与传播给全球公共卫生所带来的影响已逐步显现,MDR-TB的防治形势也变得越来越复杂。近年来,广泛耐药结核病(extensively drug resistant tuberculosis,XDR-TB)的出现使得全球结核病控制工作雪上加霜。因此,研究优化的MDR-TB化疗方案,以提高MDR-TB的治愈率,阻断其向更为难治的XDR-TB发生与发展迫在眉睫。最近,国外有关MDR-TB治疗的研究较为深入,其中不乏值得我们借鉴的经验与精髓,仔细拜读,颇有收益,愿与广大同道分享。一、MDR-TB化疗的基本策略目前WHO推荐及国外学者广泛研究的MDR-TB化疗基本策略有3种:(1)标准化治疗方案:该方案是指根据某国家或某地区有代表性的耐药监测资料和不同类别患者

引用

页码：617 / 620

共 9 条

[1] 伊朗2002—2006年使用标准化疗方案治疗耐多药肺结核患者的疗效 [J].

M.R.Masjedi ;

P.Tabarsi ;

E.Chitsaz ;

P.Baghaei ;

M.Mirsaeidi ;

M.V.Amiri ;

P.Farnia ;

P.Javanmard ;

D.Mansouri ;

A.A.Velayati ;

胡远莲 ;

何广学 .

国际结核病与肺部疾病杂志(中文版), 2008, 3 (04) :164-168

[2] Is standardized treatment appropriate for non-XDR multiple drug resistant tuberculosis cases? A clinical descriptive study [J].

Tabarsi, Payam ;

Baghaei, Parvaneh ;

Jalali, Sara ;

Farnia, Parisa ;

Chitsaz, Ehsan ;

Mirsaeidi, Mehdi ;

Kazempour, Mehdi ;

Mansouri, Davoud ;

Masjedi, Mohammad R. ;

Velayati, Ali A. .

SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2009, 41 (01) :10-13

[3] Activity of twelve second-line antimicrobial agents against Mycobacterium tuberculosis in Taiwan [J].

Lu, Po-Liang ;

Peng, Chien-Fang ;

Hwang, Jhi-Jhih ;

Chen, Yen-Hsu .

JOURNAL OF CHEMOTHERAPY, 2008, 20 (02) :202-207

[4] Treatment failure in a case of extensively drug-resistant tuberculosis associated with selection of a GyrB mutant causing fluoroquinolone resistance [J].

Veziris, N. ;

Martin, C. ;

Brossier, F. ;

Bonnaud, F. ;

Denis, F. ;

Aubry, A. .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2007, 26 (06) :423-425

[5] Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa [J].

Gandhi, Neel R. ;

Moll, Anthony ;

Sturm, A. Willem ;

Pawinski, Robert ;

Govender, Thiloshini ;

Lalloo, Umesh ;

Zeller, Kimberly ;

Andrews, Jason ;

Friedland, Gerald .

LANCET, 2006, 368 (9547) :1575-1580

[6]

Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study[J] . Vaira Leimane,Vija Riekstina,Timothy H Holtz,Evija Zarovska,Vija Skripconoka,Lorna E Thorpe,Kayla F Laserson,Charles D Wells.The Lancet . 2005 (9456)

[7]

Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru[J] . Pedro G Suárez,Katherine Floyd,Jaime Portocarrero,Edith Alarcón,Elisabetta Rapiti,Gilbert Ramos,Cesar Bonilla,Ivan Sabogal,Isabel Aranda,Christopher Dye,Mario Raviglione,Marcos A Espinal.The Lancet . 2002 (9322)

[8]

Fluoroquinolones for theTreat ment of Pul monary Tuberculosis. Susanne Moadebi,Curtis K Harder,Mark J.Fitzgerald,Kevin R.El wood,Fawziah Marra. Drugs . 2007

[9]

Community -based therapy for multidrug-resistant tuberculosis in Lima, Peru. Mitnick C, Bayona J, Palacios E, et al. The New England Journal of Medicine . 2003

← 1 →